MYCOPHENOLATE MOFETIL APPROVED FOR TREATMENT OF LUPUS NEPHRITIS IN MALAYSIA

Aspreva Pharmaceuticals Corporation reports that Mycophenolate Mofetil (MMF, CellCept(R)) has been approved for the treatment of lupus nephritis in Malaysia. On July 11, 2006, Roche Malaysia received a letter of approval from the Drug Control Authority (DCA) in Malaysia granting them approval to include lupus nephritis as an additional indication for MMF in the induction and maintenance treatment of lupus nephritis (used concomitantly with corticosteroids). Malaysia is the first country to have regulatory approval of MMF in any autoimmune disease.

CNW Group (http://www.newswire.ca/en/releases/archive/July2006/19/c8060.html)